NOFLU

NoFlu is a biotechnology company focused on the development of a universal influenza vaccine designed to provide broad-spectrum protection against diverse viral strains. The company utilizes the proprietary Epigraph vaccine platform, a computational tool that creates synthetic antigens by analyzing thousands of viral sequences to identify the most common and effective targets. By focusing on conserved epitopes, NoFlu aims to eliminate the need for annual seasonal flu shots and provide a more robust defense against potential pandemic outbreaks. The company's lead programs are currently in the pre-clinical stage, demonstrating promising results in eliciting both T-cell and B-cell immune responses. NoFlu operates as a spin-off from the University of Nebraska-Lincoln, leveraging advanced viral vector technology for vaccine delivery.